Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 2 years ago

Possible Interaction: Asymmetric Dimethylarginine and Angiotensin Ii Receptor Antagonist

Research Papers that Mention the Interaction

Angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker (ARB) are reported to reduce the serum ADMA level.
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi  •  2016  |  View Paper
angiotensin receptor blockers (… ADMA levels, but no study has compared the effect of these drugs in patients with ESRD on maintenance hemodialysis (MHD).MethodsWe evaluated the effect …), and placebo on ADMA levels in 15 patients on MHD in a double-blind, placebo-controlled, three x three cross-over study.
BMC Nephrology  •  2015  |  View Paper
Moreover, small clinical studies have shown that treatment with angiotensin receptor blockers also reduces the circulating levels of asymmetric dimethylarginine ( ADMA), an endogenous inhibitor of nitric oxide (NO) synthase.
Vascular medicine  •  2005  |  View Paper
Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers , and antioxidants are effective inhibitors of the adverse effects of ADMA.
The increased ROS production induced by ADMA was markedly inhibited by the angiotensin II receptor-blocker telmisartan , the angiotensin-converting enzyme inhibitor benazepril, the reduced form of nicotinamide-adenine dinucleotide phosphate (NADPH) oxidase inhibitor diphenyliodonium (DPI), or the antioxidant and free-radical scavenger N-acetyl-l-cysteine (NAC).
Molecular vision  •  2011  |  View Paper